Skip to content
sellWeak cluster of 210b5-1 plan

David Altshuler sold $1.6M of VRTX

EVP, Chief Scientific Officer at VERTEX PHARMACEUTICALS INC / MA. 3,231 shares at an average of $510.00, traded Mar 13, 2025, filed Mar 17, 2025.

Warning score
33
Value
$1.6M
3,231 shares
Holdings after
23,281
-12% from before
From 52-week low
+27%
low $396.64, close $502.92
From 52-week high
-3%
high $516.74, as of Mar 13, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $1.6M at market
    +25
  • Share of holdings sold
    Sold 12% of holdings
    +5
  • Cluster
    2 insiders selling within 14 days
    +8
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

VRTXOct 9, 2026 · close 510.08
Since filing Mar 17, 2025: -0.7%SPY +40.0% · excess -40.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000875320-25-000152, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Mar 13, 2025SOpen-market sale
Common Stock10b5-1
-3,231$510.00$1.6M23,281Mar 17, 2025

Related signals

Other insiders at VERTEX PHARMACEUTICALS INC / MA and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
14Weak
VRTXsell 210b5-1
VERTEX PHARMACEUTICALS INC / MA
Kristen Ambrose
SVP & Chief Accounting Officer
$173k
357 shares
-5%
13Weak
VRTXsell 210b5-1
VERTEX PHARMACEUTICALS INC / MA
Kristen Ambrose
SVP & Chief Accounting Officer
$108k
223 shares
-3%
17Weak
VRTXsell 210b5-1
VERTEX PHARMACEUTICALS INC / MA
Edward Morrow Atkinson III
EVP, Chief Technical Ops. Off.
$325k
668 shares
-3%
33Weak
VRTXsell 210b5-1
VERTEX PHARMACEUTICALS INC / MA
Kristen Ambrose
SVP & Chief Accounting Officer
$1.1M
2,195 shares
-22%
33Weak
VRTXsell 210b5-1
VERTEX PHARMACEUTICALS INC / MA
Edward Morrow Atkinson III
EVP, Chief Technical Ops. Off.
$1.4M
2,848 shares
-12%
28Weak
VRTXsell 210b5-1
VERTEX PHARMACEUTICALS INC / MA
Kristen Ambrose
SVP & Chief Accounting Officer
$634k
1,376 shares
-12%
25Weak
VRTXsell 210b5-1
VERTEX PHARMACEUTICALS INC / MA
Edward Morrow Atkinson III
EVP, Chief Technical Ops. Off.
$806k
1,751 shares
-7%
21Weak
VRTXsell 410b5-1
VERTEX PHARMACEUTICALS INC / MA
Jonathan Biller
EVP and Chief Legal Officer
$156k
347 shares
-2%
45Moderate
VRTXsell 410b5-1
VERTEX PHARMACEUTICALS INC / MA
Jeffrey M Leiden
Executive Chairman
$29M
63,781 shares
-73%
35Weak
VRTXsell 410b5-1
VERTEX PHARMACEUTICALS INC / MA
Ourania Tatsis
EVP, Chief Reg. & Quality Off.
$2.0M
4,500 shares
-9%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

David Altshuler sold $1.6M of VRTX | InsiderTell